News for Agenus Inc - Google Finance

AGENUS INC. : Positive Phase 2 Data from Agenus' Brain Cancer Vaccine ...

Wed, 01 May 2013 15:57:56 GMT

AGENUS INC. : Positive Phase 2 Data from Agenus' Brain Cancer Vaccine ...
4-traders (press release) - May 1, 2013

Lexington, MA - May 1, 2013 - Agenus Inc. (NASDAQ: AGEN) today announced that preliminary data from a Phase 2 clinical trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (Heat Shock Protein-Peptide ...

AGENUS INC. : Agenus Reports First Quarter 2013 Financial Results

Wed, 24 Apr 2013 11:26:41 GMT

AGENUS INC. : Agenus Reports First Quarter 2013 Financial Results
4-traders (press release) - Apr 24, 2013

Lexington, MA - April 24, 2013 - Agenus Inc. (NASDAQ: AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the first ...

5 of Most Volatile Micro - Cap Stocks : Star Scientific , Inc . ( STSI ...

Thu, 02 May 2013 12:31:05 GMT

5 of Most Volatile Micro - Cap Stocks : Star Scientific , Inc . ( STSI ...
REM - May 2, 2013

Star Scientific, Inc. (NASDAQ:STSI) fell -3.23% to move at $1.20 after disclosing that its second cosmetic product, Anatabloc Revitalizing Facial Serum, is now being sold on the website of vitamins and supplements retailer GNC.

Agenus Q1 13 Earnings Conference Call At 11:00 AM ET - NASDAQ.com

Wed, 24 Apr 2013 14:02:47 GMT

Agenus Q1 13 Earnings Conference Call At 11:00 AM ET - NASDAQ.com
NASDAQ - Apr 24, 2013

Agenus Q1 13 Earnings Conference Call At 11:00 AM ET. By RTT News, April 24, 2013, 10:00:00 AM EDT. Vote up. loading. (RTTNews.com) - Agenus Inc.( AGEN ) will host a conference call at 11:00 AM ETApril 24, 2013, to discuss its Q1 13 earnings results.

Glioblastoma vaccine offered better survival rates than standard care

Wed, 15 May 2013 13:43:24 GMT

Glioblastoma vaccine offered better survival rates than standard care
Healio - May 15, 2013

... protein-peptide complex-96 (HSPPC-96; Prophage G-100, Agenus Inc.) vaccine. They assigned 46 patients with newly diagnosed glioblastoma multiforme to receive the HSPPC-96 vaccination in addition to standard care of radiation and temozolomide.

Largest Nasdaq Short Interest Percent Increases as of April 30

Fri, 10 May 2013 09:28:35 GMT

Largest Nasdaq Short Interest Percent Increases as of April 30
Bloomberg - May 10, 2013

... 16.6 CYTK CYTOKINETICS INC 1,314,674 1,127,760 16.6 CCRN CROSS COUNTRY HE 465,036 398,988 16.6 RBCN RUBICON TECHNOLO 4,847,714 4,161,674 16.5 UPIP UNWIRED PLANET I 2,076,745 1,783,254 16.5 AGEN AGENUS INC 1,343,896 ...

Agenus Downgraded to Neutral at Zacks (AGEN)

Mon, 29 Apr 2013 19:12:36 GMT

Agenus Downgraded to Neutral at Zacks (AGEN)
Mideast Time - Apr 29, 2013

Agenus Inc., formerly Antigenics Inc., develops and commercializes immunotherapies for cancer and infectious diseases. To view Zacks' full report, visit www.

Supreme Court Declines To Hear Eli Lilly's "Promise Of The Patent" Appeal

Fri, 17 May 2013 10:46:18 GMT

Supreme Court Declines To Hear Eli Lilly's "Promise Of The Patent" Appeal
Mondaq News Alerts (registration) - May 17, 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Eli Lilly Canada Inc v Novopharm Ltd., 2012 FCA 232. This proceeding concerned the standard of utility and, specifically, the "promise of the ...

Variety and hardiness of coneflowers make them a popular perennial

Thu, 16 May 2013 11:15:30 GMT

Variety and hardiness of coneflowers make them a popular perennial
Plain Dealer - May 16, 2013

Echinacea is a genus and the botanical name for the broad spectrum of coneflowers, which not only vary in color, but also height and types of leaves.

AGEN's Brain Cancer Vaccine Works, AVEO On Watch, PSDV Gets Decision Date

Thu, 02 May 2013 02:29:34 GMT

AGEN's Brain Cancer Vaccine Works, AVEO On Watch, PSDV Gets Decision Date
NASDAQ - May 2, 2013

(RTTNews.com) - Agenus Inc. ( AGEN ) said that its brain cancer vaccine candidate - Prophage G-100, plus the standard of care demonstrated a 146% increase in progression free survival and a 60% increase in overall survival compared to the standard of ...